viewShield Therapeutics PLC

Shield Therapeutics - PT20 paper publication

RNS Number : 1127T
Shield Therapeutics PLC
16 July 2020

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")


PT20 paper publication

Demonstrates statistically significant and dose-dependent reduction in serum phosphate concentration


London, UK, 16 July 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), notes the recent publication in Nephrology Dialysis Transplantation of a paper concerning PT20, Shield's iron-based phosphate binder.


PT20 is a novel iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia (when there is too much phosphorus present in the blood) related to dialysis or non-dialysis dependent chronic kidney disease (CKD). The publication Nephrology Dialysis Transplantation has published a paper entitled "Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease." The study, which was funded by Shield, was a pivotal study to support marketing authorisation submissions and was a double-blind, parallel-group, placebo-controlled, dose-ranging study in which the efficacy and safety of 28 days of oral PT20 treatment were evaluated in patients with dialysis-dependent CKD. Participants were randomly assigned to receive PT20 or placebo three times daily. The study demonstrated that PT20 treatment for 28 days resulted in a statistically significant and dose-dependent reduction in serum phosphate concentration and was generally well tolerated.


The paper is available online here:



Shield has agreed with the US FDA that PT20 requires only one further pivotal Phase III study after which regulatory filings for marketing approval would be expected to follow. Shield will first develop a new formulation of PT20 which will allow the Phase III study to be carried out and which will be suitable for commercial use. It is anticipated that the formulation work could start in the second half of 2020 which would potentially allow the Phase III study to start in 2022, subject to finance being available.



For further information please contact:


Shield Therapeutics plc


Tim Watts, CEO

+44 (0)20 7186 8500

Karen Chandler Smith, Investor Relations



Nominated Adviser and Joint Broker


Peel Hunt LLP


James Steel/Dr Christopher Golden

+44 (0)20 7418 8900


Joint Broker

finnCap Ltd     

Geoff Nash/Matt Radley/Alice Lane                                             



+44 (0)20 7220 0500



 Financial PR & IR Advisor


Walbrook PR

+44 (0)20 7933 8780 or [email protected]

Paul McManus/Lianne Cawthorne

+44 (0)7980 541 893 / +44 (0)7584 391 303



About Shield Therapeutics plc


Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market.  Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 


For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Shield Therapeutics PLC

Price: 131.5

Market: LSE
Market Cap: £154.1 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Market report: FTSE falters as US Federal Reserve decision takes centre stage

The FTSE 100 mixed this Wednesday after the (OECD) said the global economy is set to shrink 4.5% in 2020, which is not as bad as the 6% collapse it had forecast in June. Also today - the UK’s inflation fell to 0.2% in August, from 1% in July - due largely to the ‘Eat out to help out’ government...

1 week, 6 days ago